OpGen: Upside in the fight against superbugs?

The fight against so-called superbugs costs the United States an estimated $20bn each year and is set to spiral into a global pandemic, causing up to 10 million deaths by 2050. (World Health Organisation)

According to our research, Nasdaq-listed OpGen, which has developed fast testing technology designed to stave off this bleak future, may see upside soon. Our current valuation of OpGen is $2.67 per share, versus the 12-month analyst consensus valuation of $4.56. On 8 July 2021 the share price closed at $2.23.

As OpGen moves out of development and into commercialisation, positive newsflow should transform the share price performance.